What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Sarin, S K ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; AMANTADINE; ANTIOXIDANT; ANTIVIRUS AGENT; BING GAN LIU; BIOLOGICAL RESPONSE MODIFIER; DAI SHO TO; GLYCYRRHIZIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HERBACEOUS AGENT; IMMUNOMODULATING AGENT; INDOMETACIN; INTERFERON; IRON; KETOPROFEN; NEOMINOPHAGEN C; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; ORENGEDOKU TO; RIBAVIRIN; RIMANTADINE; SHO SEIRUY TO; SHOSAIKOTO GO KEISHIKASHAKUYAKUTO; TENOXICAM; THYMOSIN ALPHA1; TJ 19; TJ 8; TOKISHAKUYAKU SAN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; XIAO CHAI HU TANG;

ADJUVANT THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIET RESTRICTION; DIET THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; HEPATITIS C; HERBAL MEDICINE; HUMAN; IMMUNOMODULATION; MONOTHERAPY; OXIDATIVE STRESS; PHLEBOTOMY; PHYLLANTHUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033920185     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02117.x     Document Type: Conference Paper

References (61)

1. Schalm SW, Weiland O, Hansen BE et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999; 117: 408-13.
2. Johanson IF. Hepatitis C therapy: is it really worth it? Am. J. Gastroenterol. 1999; 94: 1412-13.
3. Ware Jr JE, Bayliss MS, Mannocchia M, Davis GL. Health related quality of life in chronic hepatitis C: impact of disease and treatment response (The interventional therapy group). Hepatology 1999; 30: 550-5.
4. Takano S, Ito Y, Yokusuka O et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558-64.
5. Lu CL, Chan CY, Hwang SJ et al. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 1995; 10: 432-7.
6. Nakamura K, Yonedo M, Takamoto S et al. Effect of ursodeoxycholic acid on autoimmune-associated chronic hepatitis C. J. Gastroenterol. Hepatol. 1999; 14: 413-18.
7. Boucher E, Jouanolle H, Andre P et al. Interferon and ursodeoxychloic acid combined therapy in the treaternent of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am. J. Gastroenterol. 1995; 21: 322-7.
8. Angelico M, Gandin C, Pescarmona E et al. Recombinant Interferon alpha and ursodeoxycholic acid versus interferon alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am. J. Gastroenterol. 1995; 90: 263-9.
9. Tanaka K, Kondo M, Sakagucbi T et al. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial. J. Gastroenterol. Hepatol. 1996; 11: 1155-60.
10. Kiso S, Kwata S, Imai Y et al. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyl transpeptidase levels. J. Gastroenterol. 1996; 31: 75-80.
11. Clerici C, Distrutti E, Gentilli G et al. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis. Minerva Med. 1997; 88: 219-25.
12. Senturk H, Uzunalimoglu O, Batur Y et al. Long-term efficacy of interferon alpha and ursodeoxycholic acid in the treatment of chronic type C hepatitis. Dig. Dis. Sci. 1997; 42: 1438-44.
13. Abdelmalck MF, Harrison NIE, Gross JB et al. Treatment of chronic hepatitis C with interferon with or without ursodeoxvcholic acid: a randomized prospective trial. J. Clin. Gastroenterol. 1998; 26: 130-4.
14. Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J. Hepatol. 1999; 22: 268-71.
15. Girelle CM, Mirata C, Casiraghi A. Effect of blood letting on serum aminotransferase levels of patients with chronic hepatitis C and iron overload. Rec. Prog. Med. 1998; 89: 241-4.
16. Fong TL, Han SH, Tsai NC et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J. Hepatol. 1998; 28: 369.
17. Tsai NC, Zuckerman E, Han SH et al. Effect of iron depletion on long-term response to interferon alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am. J. Gastroenterol. 1997; 92: 1831-4.
18. Fargion S, Fracanzani AL, Sampietro M et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 1997; 9: 497-503.
19. Piperno A, Sampictro M, D'Alba R et al. Iron stores, response to alpha interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16: 248-54.
20. Kageyama F, Kobayashi Y, Murohisa G et al. Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C. Biol. Trace Elem. Res. 1998; 64: 185-96.
21. Guyader D, Boucher E, Andre P et al. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am. J. Gastroenterol. 1999; 94: 1696-8.
22. Tandon N, Thakur V, Guptan RC, Sarin SK. Beneficial effects of an indigenous low iron diet on serum indicators of iron status in chronic liver disease patients. Br. J. Nutr. 1999 (in press.)
23. Guptan RC, Malhotra S, Khandekar P, Sarin SK. Influence of low iron diet on the efficacy of interferon therapy in patients with chronic liver disease. In: Proceedings of IXth Biennial Scientific Meeting of APASL, Kuala Lumpur, Malaysia, 1994.
24. Tanaka K, Ikeda M, Nazaki A et al. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn. J. Cancer Res. 1999; 90: 367-71.
25. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig. Dis. Sci. 1997; 42: 1681-7.
26. Pimstone 1998.
27. Tabone M, Ercole E, Zaffino C et al. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV RNA in chronic hepatitis C patients. Ital. J. Gastroenterol. Hepatol. 1999; 30: 611-13.
28. Fong TI, Freid MW, Clarke-Platt J et al. A pilot study of rimantidine for patients with chronic hepatitis C unresponsive to interferon therapy. Am. J. Gastroenterol. 1999; 94: 990-3.
29. Sherman KE, Sickle TJ, Aranda-Michel J et al. Rimantadine for treatment of chronic hepatitis C infection in liver transplant recipients. Liver Transplant. Surg. 1999; 5: 25-8.
30. Finder JA, Daurich JR, Igartua E et al. Amantadine HCl alone and associated with recombinant alpha interferon 2a during a short term therapy in chronic HCV infection. Hepatology 1997; 26: 217A.
31. Khalili M, Olmeda M, Denham CB et al. A comparison of combination therapy with interferon and ribavirin versus interferon and amantadine in interferon non-responders with chronic hepatitis C. Hepatology 1998; 28: 169A.
32. Younossi ZM, Mullen K, Zakko W et al. Interferon alpha 2b and ribavirin versus interferon alpha 2b and amantadine for chronic hepatitis C (non-responder): a multicenter randomized double blind trial. Hepatology 1998; 28: 284A.
33. Brillianti S, Foli M, Di Tomaso M et al. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alfa non-responders. Ital. J. Gastroenterol. Hepatol. 1999; 31: 130-4.
34. Martin J, Navas S, Fernandez M et al. In vitro effect of amantadine and interferon alfa 2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus infected patients. Antiviral Res. 1999; 42: 59-70.
35. Chojkier M, Houglum K, Lee KS et al. Long- and short-term D alpha tocopherol supplementation inhibits liver collagen alpha (1) gene expression. Am. J. Physiol. 1998; G1480-5.
36. von Herbay A, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double blind, placebo-controlled study. Free Radic. Res. 1997; 27: 599-603.
37. Houglum K, Venkatramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069-73.
38. Zarski JP, Maynard-Muet M, Chousterman S et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998; 27: 862-71.
39. Anderson FH, Zency L, Yoshida EM, Rock NR. Failure of ketoprofen and interferon combination therapy to improve interteron-resistant chronic hepatitis C. Can. J. Gastroenterol. 1997; 11: 294-7.
40. Giambartolomei S, Artini M, Almerighi C et al. Non-steroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. Hepatology 1999; 30: 510-16.
41. van Rossum TG, Vulto AG, de Man RA et al. Glycyrrhizin as a potential treatment for chronic hepatitis C (Review). Aliment. Pharmacol Ther. 1998; 12: 199-205.
42. Yamashiki M, Nishimura A, Suzuki H et al. Effects of the Japanese herbal medicine 'Sho-saiko-to' (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. Hepatology 1997; 25: 1390-7.
43. Yamashiki M, Nishimura A, Nobori T et al. In vitro effects of sho-saikoto-to on production of granulocyte colony stimulating factor by mononuclear cells from patients with chronic hepatitis C. Int. J. Immunopharmacol. 1997; 19: 381-5.
44. Kayono K, Sakaida I, Uchida K, Okita K. Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatatic stellate cells. J. Hepatol. 1998; 29: 642-9.
45. Sakaguchi. S, Tsutsumi E, Yokota K. Preventive effects of a traditional Chinese medicine (sho-saiko-to) against oxygen toxicity and membrane damage during endotoxemia. Biol. Pharm. Bull. 1993; 16: 782-6.
46. Shimizu I, MaYR, Mizobuchi Y et al. Effects of sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-60.
47. Arase Y, Ikeda K, Murashima N et al. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-500.
48. Okuno T, Arai K, Shindo M. Efficacy of interferon combined glycyrrhizin therapy in patients with chronic hepatitis C resistant to interferon therapy. Nippon Rinsho 1994; 52: 1823-7.
49. Yamashiki M, Nishimura A, Nobori T et al. In vitro effects of sho-saiko-to on production of granulocyte colony stimulating factor by mononuclear cells from patients with chronic hepatitis C. Int. J. Immunopharmacol. 1997; 19: 381-5.
50. You S, Zbou M, Fang T et al. A clinical study on bing gan ling oral liquid for treatment of hepatitis C. J. Trad. Chin. Med. 1998; 18: 209-14.
51. Mutchnick MG, Elirinpreis MN, Kinzie TL. Perspectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res. 1994; 29: 245-50.
52. Di Bisceglie M. Thymus derived peptides for chronic viral hepatitis: have they fulfilled their promise? Dig. Dis. Sci. 1996; 14: 331-3.
53. Andreone P, Cursaro C, Gramenzi A et al. A double-blind, placebo controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver 1996; 16: 207-10.
54. Rasi G, DiVirgillo D, Mutchnick MG et al. Combination thymosin alpha I and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 1996; 39: 679-83.
55. Sherman ICE, Sjogren M, Creager RL et al. Combination therapy with thymosin alpha I and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo controlled double-blind trial. Hepatology 1998; 27: 1128-35.
56. Moscarella S, Buzzelli G, Romanelli RG et al. Interferon and thymosin combination therapy in naïve patients with chronic hepatitis C: preliminary results. Liver 1998; 18: 366-9.
57. Bonkovsky HL. Therapy of chronic hepatitis C: other options. Hepatology 1997; 26: S143-51.
58. Tsutsumi M, Takada A, Takase S, Sawada M. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study. J. Gastroenterol. Hepatol. 1996; 11: 1006-11.
59. Komatsu M, Ishii T, Ono T et al. Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration. Can. J. Gastroenterol. 1997; 11: 507-11.
60. Negro F, Male P, Perrin L et al. Treatment of chronic hepatitis C with alpha interferon plus ofloxacin in patients not responding to alpha-interferon alone. J. Hepatol. 1998; 29: 369-74.
61. Shiffman MI, Hofmann CM, Luketic VA et al. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J. Hepatol. 1998; 28: 3821-9.